Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?

References

• Nicolle C, Cuenod A, Baizot L. Etude experimentale du trachome. Arch Instit Pasteur de Tunis. 1913;4:82–157.
   Google Scholar
• Schachter J, Dawson CR. Human chlamydial infections. Littleton, Mass: PSG Pub. Co.;1978. 273. xi.
   Google Scholar
• Taylor HR. Trachoma: a blinding scourge from the Bronze Age to the twenty-first century. 1st ed. Victoria, Australia: Haddington Press Pry Ltd; 2008.
   Google Scholar
• Taylor HR. Doyne Lecture: trachoma, is it history? Eye (Lond). 2009;23(11):22–2007.
   Web of Science ®Google Scholar
• Collier LH. Experiments with trachoma vaccines. Experimental system using inclusion blennorrhoea virus. Lancet. 1961;277(7181):795–800.
   Google Scholar
• Collier LH, Blyth WA. Immunogenicity of experimental trachoma vaccines in baboons. I. Experimental methods, and preliminary tests with vaccines prepared in chick embryos and in HeLa cells. J Hyg (Lond). 1966;64(4):28–513.
   Google Scholar
• Grayston JT, Woolridge RL, Wang S. Trachoma vaccine studies on Taiwan. Ann N Y Acad Sci. 1962;98:67–352.
   Web of Science ®Google Scholar
• Grayston JT, Woolridge RL, Wang SP, et al. Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine. 1963;112:95–589.
   Google Scholar
• Grayston JT, Wang SP, Yeh LJ, et al. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis. 1985;7(6):25–717.
   Google Scholar
• Nichols RL, Bell SD Jr., Murray ES, et al. Studies on trachoma. V. Clinical observations in a field trial of bivalent trachoma vaccine at three dosage levels in Saudi Arabia. Am J Trop Med Hyg. 1966;15(4):47–639.
   Web of Science ®Google Scholar
• Nichols RL, Bell SD Jr., Haddad NA, et al. Studies on trachoma. VI. Microbiological observations in a field trial in Saudi Arabia of bivalent rachoma vaccine at three dosage levels. Am J Trop Med Hyg. 1969;18(5):30–723.
   Web of Science ®Google Scholar
• Bietti G, Werner GH. Trachoma: prevention and treatment, by Giambattista Bietti and Georges H. Werner. Springfield, Ill.: Thomas;1967. 227. xv.
   Google Scholar
• Woolridge RL, Grayston JT, Chang IH, et al. Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children. Am J Ophthalmol. 1967;63(Suppl 5):50–1645.
   Google Scholar
• Sowa S, Sowa J, Collier LH, et al. Trachoma vaccine field trials in The Gambia. J Hyg (Lond). 1969;67(4):699–717.
   PubMedGoogle Scholar
• Karunakaran KP, Yu H, Foster LJ, et al. Using MHC molecules to define a Chlamydia T cell vaccine. Methods Mol Biol. 2016;1403:32–419.
   Google Scholar
• Poston TB, Darville T. Chlamydia trachomatis: protective adaptive responses and prospects for a vaccine. Curr Top Microbiol Immunol. 2016.
   PubMed Web of Science ®Google Scholar
• Yu H, Karunakaran KP, Jiang X, et al. Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis. Expert Rev Vaccines. 2016;15(8):88–977.
   Web of Science ®Google Scholar
• Gottlieb SL, Deal CD, Giersing B, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps. Vaccine. 2016;34(26):47–2939.
   Web of Science ®Google Scholar
• Liang S, Bulir D, Kaushic C, et al. Considerations for the rational design of a Chlamydia vaccine. Hum Vaccin Immunother. 2017;13(4):5–831.
   Web of Science ®Google Scholar
• de la Maza LM, Zhong G, Brunham RC. Update on Chlamydia trachomatis Vaccinology. Clin Vaccine Immunol. 2017;24(4).
   PubMedGoogle Scholar
• Gottlieb SL, Johnston C. Future prospects for new vaccines against sexually transmitted infections. Curr Opin Infect Dis. 2017;30(1):77–86.
   PubMed Web of Science ®Google Scholar
• Hafner LM, Timms P. Development of a Chlamydia trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects. Expert Rev Vaccines. 2018;17(1):57–69.
   PubMed Web of Science ®Google Scholar
• Phillips S, Quigley BL, Timms P. Seventy years of chlamydia vaccine research - limitations of the past and directions for the future. Front Microbiol. 2019;10:70.
   PubMed Web of Science ®Google Scholar
• Lizarraga D, Carver S, Timms P. Navigating to the most promising directions amid complex fields of vaccine development: a chlamydial case study. Expert Rev Vaccines. 2019;18(12):37–1323.
   Web of Science ®Google Scholar
• Poston TB, Gottlieb SL, Darville T. Status of vaccine research and development of vaccines for Chlamydia trachomatis infection. Vaccine. 2019;37(50):94–7289.
   Web of Science ®Google Scholar
• Zhong G, Brunham RC, de la Maza LM, et al. National Institute of allergy and infectious diseases workshop report: “Chlamydia vaccines: the way forward”. Vaccine. 2019;37(50):54–7346.
   Web of Science ®Google Scholar
• de la Maza LM, Pal S, Olsen AW, et al. Chlamydia vaccines. Tan M, Hegemann JH, Sutterlin C, editors. Norfolk, UK: Caister Academic Press; 2020. p. 83–339.
   Google Scholar
• Order MJ. Chlamydiales and family Chlamydiaceae. In: Nr K, editor. Bergey’s Manual of Systemic Bacteriology. Baltimore: Williams and Wilkins; 1984. p. 729.
   Google Scholar
• Moulder JW. Interaction of Chlamydiae and host cells in vitro. Microbiol Rev. 1991;55(1):90–143.
   Google Scholar
• Lee JK, Enciso GA, Boassa D, et al. Replication-dependent size reduction precedes differentiation in Chlamydia trachomatis. Nat Commun. 2018;9(1):45.
   PubMedGoogle Scholar
• Matsumoto A. Structural characteristics of chlamydia bodies. In: Barron A, editor. Microbiology of Chlamydia. Boca Raton: CRC Press Inc; 1988. p. 21–45.
   Google Scholar
• de la Maza LM, Peterson EM. Scanning electron microscopy of McCoy cells infected with Chlamydia trachomatis. Exp Mol Pathol. 1982;36(2):26–217.
   Web of Science ®Google Scholar
• Sixt BS. Host cell death during infection with Chlamydia: a double-edged sword. FEMS Microbiol Rev. 2021;45(1).
   PubMed Web of Science ®Google Scholar
• Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun. 1981;31(3):76–1161.
   Web of Science ®Google Scholar
• Hatch TP. Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? J Bacteriol. 1996;178(1):1–5.
   PubMed Web of Science ®Google Scholar
• Stephens RS, Lammel CJ. Chlamydia outer membrane protein discovery using genomics. Curr Opin Microbiol. 2001;4(1):16–20.
   PubMed Web of Science ®Google Scholar
• Tanner M, Harris J, Pace N. Molecular phylogeny of Chlamydia and relatives. In: Stephens R, editor. Chlamydia: intracellular biology, pathogenesis and immunity. Washington: ASM; 1999. p. 1–8.
   Google Scholar
• Liu X, Afrane M, Clemmer DE, et al. Identification of Chlamydia trachomatis outer membrane complex proteins by differential proteomics. J Bacteriol. 2010;192(11):60–2852.
   Web of Science ®Google Scholar
• Saka HA, Thompson JW, Chen YS, et al. Quantitative proteomics reveals metabolic and pathogenic properties of Chlamydia trachomatis developmental forms. Mol Microbiol. 2011;82(5):203–1185.
   Web of Science ®Google Scholar
• Pal S, Mirzakhanyan Y, Gershon P, et al. Induction of protection in mice against a respiratory challenge by a vaccine formulated with exosomes isolated from Chlamydia muridarum infected cells. NPJ Vaccines. 2020;5(1):87.
   PubMed Web of Science ®Google Scholar
• Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted Infections in 2012 based on systematic Review and global reporting. PLoS One. 2015;10(12):e0143304.
   PubMed Web of Science ®Google Scholar
• Price MJ, Ades AE, Welton NJ, et al. Proportion of pelvic inflammatory disease cases caused by Chlamydia trachomatis: consistent picture from different methods. J Infect Dis. 2016;214(4):24–617.
   Web of Science ®Google Scholar
• CDC Sexually transmitted disease surveillance. 2018. prevention DoS. editor. U.S. Department of Health and Human Services;Atlanta:2019.1–168.
   Google Scholar
• Price MJ, Ades AE, Soldan K, et al. The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. Health Technol Assess. 2016;20(22):1–250.
   PubMed Web of Science ®Google Scholar
• Brunham RC, Paavonen J. Reproductive system infections in women: lower genital tract syndromes. Pathog Dis. 2020;78(5).
   Web of Science ®Google Scholar
• Korenromp EL, Wi T, Resch S, et al. Costing of National STI Program Implementation for the Global STI Control Strategy for the Health Sector, 2016–2021. PLoS One. 2017;12(1):e0170773.
   PubMed Web of Science ®Google Scholar
• Eisinger RW, Erbelding E, Fauci AS. Refocusing research on sexually transmitted infections. J Infect Dis. 2020;222(9):4–1432.
   PubMed Web of Science ®Google Scholar
• Westrom L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992;19(4):92–185.
   PubMed Web of Science ®Google Scholar
• Chan PA, Robinette A, Montgomery M, et al. Extragenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a Review of the literature. Infect Dis Obstet Gynecol. 2016;2016:5758387.
   PubMedGoogle Scholar
• Mackern-Oberti JP, Motrich RD, Damiani MT, et al. Male genital tract immune response against Chlamydia trachomatis infection. Reproduction. 2017;154(4):R99–R110.
   PubMed Web of Science ®Google Scholar
• Bryan ER, Kim J, Beagley KW, et al. Testicular inflammation and infertility: could chlamydial infections be contributing? Am J Reprod Immunol. 2020;84(3):e13286.
   PubMed Web of Science ®Google Scholar
• Bryan ER, Redgrove KA, Mooney AR, et al. Chronic testicular Chlamydia muridarum infection impairs mouse fertility and offspring development. Biol Reprod. 2020;102(4):888–901.
   PubMed Web of Science ®Google Scholar
• Blatt AJ, Lieberman JM, Hoover DR, et al. Chlamydial and gonococcal testing during pregnancy in the United States. Am J Obstet Gynecol. 2012;207(1):55 e1–8.
   Web of Science ®Google Scholar
• Ditkowsky J, Shah KH, Hammerschlag MR, et al. Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States. BMC Infect Dis. 2017;17(1):155.
   PubMedGoogle Scholar
• Williams CL, Harrison LL, Llata E, et al. Sexually transmitted diseases among pregnant women: 5 States, United States, 2009–2011. Matern Child Health J. 2018;22(4):45–538.
   Web of Science ®Google Scholar
• Ziklo N, Huston WM, Hocking JS, et al. Chlamydia trachomatis genital tract infections: when host immune response and the microbiome collide. Trends Microbiol. 2016;24(9):65–750.
   Web of Science ®Google Scholar
• Gratrix J, Singh AE, Bergman J, et al. Evidence for increased Chlamydia case finding after the introduction of rectal screening among women attending 2 Canadian sexually transmitted infection clinics. Clin Infect Dis. 2015;60(3):398–404.
   PubMed Web of Science ®Google Scholar
• Cole MJ, Field N, Pitt R, et al. Substantial underdiagnosis of lymphogranuloma venereum in men who have sex with men in Europe: preliminary findings from a multicentre surveillance pilot. Sex Transm Infect. 2020;96(2):42–137.
   Web of Science ®Google Scholar
• Farris CM, Morrison RP. Vaccination against Chlamydia genital infection utilizing the murine C muridarum model. Infect Immun. 2011;79(3):96–986.
   Web of Science ®Google Scholar
• Labuda JC, McSorley SJ. Diversity in the T cell response to Chlamydia-sum are better than one. Immunol Lett. 2018;202:59–64.
   PubMed Web of Science ®Google Scholar
• Nogueira CV, Zhang X, Giovannone N, et al. Protective immunity against Chlamydia trachomatis can engage both CD4+ and CD8+ T cells and bridge the respiratory and genital mucosae. J Immunol. 2015;194(5):29–2319.
   PubMed Web of Science ®Google Scholar
• Johnson RM, Olivares-Strank N, Peng G. A class II-restricted CD813 T cell clone protects during Chlamydia muridarum genital tract infection. J Infect Dis. 2020;221(11):1895–1906.
   Web of Science ®Google Scholar
• Morrison SG, Morrison RP. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infect Immun. 2000;68(5):9–2870.
   Web of Science ®Google Scholar
• Farris CM, Morrison SG, Morrison RP. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun. 2010;78(10):83–4374.
   Web of Science ®Google Scholar
• Pal S, Theodor I, Peterson EM, et al. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine. 1997;15(5):82–575.
   Web of Science ®Google Scholar
• Li LX, McSorley SJ. A re-evaluation of the role of B cells in protective immunity to Chlamydia infection. Immunol Lett. 2015;164(2):88–93.
   PubMed Web of Science ®Google Scholar
• Pal S, Bravo J, Peterson EM, et al. Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Infect Immun. 2008;76(12):7–5581.
   Web of Science ®Google Scholar
• Naglak EK, Morrison SG, Morrison RP. Neutrophils are central to antibody-mediated protection against genital Chlamydia. Infect Immun. 2017;85(10). DOI:10.1128/IAI.00409-17
   PubMed Web of Science ®Google Scholar
• Russell AN, Zheng X, O’Connell CM, et al. Analysis of factors driving incident and ascending infection and the role of serum antibody in Chlamydia trachomatis genital tract infection. J Infect Dis. 2016;213(4):31–523.
   PubMed Web of Science ®Google Scholar
• Bakshi RK, Gupta K, Jordan SJ, et al. An adaptive Chlamydia trachomatis-specific IFN-gamma-producing CD4(+) T cell response is associated with protection against Chlamydia reinfection in women. Front Immunol. 2018;9:1981.
   PubMed Web of Science ®Google Scholar
• Brunham RC, Kuo CC, Cles L, et al. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect Immun. 1983;39(3):41–491.
   Web of Science ®Google Scholar
• Darville T, Albritton HL, Zhong W, et al. Anti-chlamydia IgG and IgA are insufficient to prevent endometrial chlamydia infection in women, and increased anti-chlamydia IgG is associated with enhanced risk for incident infection. Am J Reprod Immunol. 2019;81(5):e13103.
   PubMed Web of Science ®Google Scholar
• Ogendi BMO, Bakshi RK, Gupta K, et al. T cell phenotypes in women with Chlamydia trachomatis infection and influence of treatment on phenotype distributions. Microbes Infect. 2018;20(3):84–176.
   Web of Science ®Google Scholar
• Ogendi BMO, Bakshi RK, Sabbaj S, et al. Distinct peripheral vs mucosal T-cell phenotypes in Chlamydia-infected women. Am J Reprod Immunol. 2017;78(6):e12768.
   PubMed Web of Science ®Google Scholar
• Poston TB, Lee DE, Darville T, et al. Cervical cytokines associated with Chlamydia trachomatis susceptibility and protection. J Infect Dis. 2019;220(2):9–330.
   Web of Science ®Google Scholar
• Zheng X, O’Connell CM, Zhong W, et al. Discovery of blood transcriptional endotypes in women with pelvic inflammatory disease. J Immunol. 2018;200(8):56–2941.
   Web of Science ®Google Scholar
• Batteiger TA, Spencer N, Washam CL, et al. Endocervical miRNA expression profiles in women positive for Chlamydia trachomatis with clinical signs and/or symptoms are distinct from those in women positive for Chlamydia trachomatis without signs and symptoms. Infect Immun. 2020;88(10). DOI:10.1128/IAI.00057-20.
   PubMed Web of Science ®Google Scholar
• Yeruva L, Pouncey DL, Eledge MR, et al. MicroRNAs modulate pathogenesis resulting from Chlamydial infection in mice. Infect Immun. 2017;85(1). DOI:10.1128/IAI.00768-16.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, He Q, Joseph K, et al. Role of T lymphocytes in the pathogenesis of Chlamydia disease. J Infect Dis. 2009;200(6):34–926.
   Web of Science ®Google Scholar
• Vicetti Miguel RD, Quispe Calla NE, Pavelko SD, et al. Intravaginal Chlamydia trachomatis challenge infection elicits Th1 and Th17 immune responses in mice that promote pathogen clearance and genital tract damage. PLoS One. 2016;11(9):e0162445.
   PubMed Web of Science ®Google Scholar
• Morrison SG, Giebel AM, Toh E, et al. A genital infection-attenuated Chlamydia muridarum mutant infects the gastrointestinal tract and protects against genital tract challenge. mBio. 2020;11(6):6.
   Web of Science ®Google Scholar
• Stary G, Olive A, Radovic-Moreno AF, et al. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015;348(6241):aaa8205.
   PubMed Web of Science ®Google Scholar
• Pal S, Theodor I, Peterson EM,  et al. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect Immun. 1997;65(8):9–3361.
   PubMed Web of Science ®Google Scholar
• Yu H, Karunakaran KP, Jiang X, et al. Comparison of Chlamydia outer membrane complex to recombinant outer membrane proteins as vaccine. Vaccine. 2020;38(16):91–3280.
   Web of Science ®Google Scholar
• Stephens RS, Kalman S, Lammel C, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science. 1998;282(5389):9–754.
   Web of Science ®Google Scholar
• Fitch WM, Peterson EM, de la Maza LM. Phylogenetic analysis of the outer-membrane-protein genes of Chlamydiae, and its implication for vaccine development. Mol Biol Evol. 1993;10(4):892–913.
   PubMed Web of Science ®Google Scholar
• de la Maza LM, Peterson EM. Vaccines for Chlamydia trachomatis infections. Curr Opin Invest Drugs. 2002;3(7):6–980.
   Google Scholar
• Nikaido H. Porins and specific channels of bacterial outer membranes. Mol Microbiol. 1992;6(4):42–435.
   Web of Science ®Google Scholar
• Nikaido H. Porins and specific diffusion channels in bacterial outer membranes. J Biol Chem. 1994;269(6):8–3905.
   Web of Science ®Google Scholar
• Stephens RS, Sanchez-Pescador R, Wagar EA, et al. Diversity of Chlamydia trachomatis major outer membrane protein genes. J Bacteriol. 1987;169(9):85–3879.
   Web of Science ®Google Scholar
• Baehr W, Zhang YX, Joseph T, et al. Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc Natl Acad Sci U S A. 1988;85(11):4–4000.
   Web of Science ®Google Scholar
• Stephens RS, Wagar EA, Schoolnik GK. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J Exp Med. 1988;167(3):31–817.
   Web of Science ®Google Scholar
• Ortiz L, Demick KP, Petersen JW, et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J Immunol. 1996;157(10):67–4554.
   Web of Science ®Google Scholar
• Sun G, Pal S, Sarcon AK, et al. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J Bacteriol. 2007;189(17):35–6222.
   Web of Science ®Google Scholar
• Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun. 2001;69(10):7–6240.
   Web of Science ®Google Scholar
• Pal S, Peterson EM, de la Maza LM. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun. 2005;73(12):60–8153.
   Web of Science ®Google Scholar
• Pal S, Tatarenkova OV, de la Maza LM. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge. Immunology. 2015;146(3):43–432.
   Web of Science ®Google Scholar
• Berry LJ, Hickey DK, Skelding KA, et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun. 2004;72(2):28–1019.
   Web of Science ®Google Scholar
• Carmichael JR, Pal S, Tifrea D, de la Maza LM. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine. 2011;29(32):83–5276.
   Web of Science ®Google Scholar
• Pal S, Cruz-Fisher MI, Cheng C, et al. Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a Chlamydia muridarum genital challenge. NPJ Vaccines. 2020;5(1):90.
   PubMed Web of Science ®Google Scholar
• Verma R, Sahu R, Dixit S, et al. The Chlamydia M278 major outer membrane peptide encapsulated in the Poly(lactic acid)-Poly(ethylene glycol) nanoparticulate self-adjuvanting delivery system protects mice against a Chlamydia muridarum genital tract challenge by stimulating robust systemic and local mucosal immune responses. Front Immunol. 2018;9:2369.
   PubMed Web of Science ®Google Scholar
• O’Meara CP, Armitage CW, Kollipara A, et al. Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia. Mucosal Immunol. 2016;9(4):88–1076.
   Web of Science ®Google Scholar
• Tifrea DF, Pal S, de la Maza LM, et al. Chlamydia trachomatis MOMP vaccine elicits cross-serogroup protection in mice against vaginal shedding and infertility. J Infect Dis. 2020;221(2):191–200.
   PubMed Web of Science ®Google Scholar
• Wern JE, Sorensen MR, Olsen AW, et al. Simultaneous subcutaneous and intranasal administration of a CAF01-adjuvanted Chlamydia vaccine elicits elevated IgA and protective Th1/Th17 responses in the genital tract. Front Immunol. 2017;8:569.
   PubMed Web of Science ®Google Scholar
• Olsen AW, Follmann F, Erneholm K, et al. Protection against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein. J Infect Dis. 2015;212(6):89–978.
   Web of Science ®Google Scholar
• Olsen AW, Lorenzen EK, Rosenkrands I, et al. Protective effect of vaccine promoted neutralizing antibodies against the intracellular pathogen Chlamydia trachomatis. Front Immunol. 2017;8:1652.
   PubMed Web of Science ®Google Scholar
• Erneholm K, Lorenzen E, Boje S, et al. Genital infiltrations of CD4(+) and CD8(+) T Lymphocytes, IgA(+) and IgG(+) plasma cells and intra-mucosal lymphoid follicles associate with protection against genital Chlamydia trachomatis infection in minipigs intramuscularly immunized with UV-inactivated bacteria adjuvanted with CAF01. Front Microbiol. 2019;10:197.
   PubMed Web of Science ®Google Scholar
• Lorenzen E, Follmann F, Bøje S, et al. Intramuscular priming and intranasal boosting induce strong genital immunity through secretory IgA in minipigs infected with Chlamydia trachomatis. Front Immunol. 2015;6:6.
   PubMed Web of Science ®Google Scholar
• Boje S, Olsen AW, Erneholm K, et al. A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-gamma(+) CMI responses protects against a genital infection in minipigs. Immunol Cell Biol. 2016;94(2):95–185.
   Web of Science ®Google Scholar
• Abraham S, Juel HB, Bang P, et al. Safety and immunogenicity of the Chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, Phase 1 trial. Lancet Infect Dis. 2019;19(10):100–1091.
   Web of Science ®Google Scholar
• Henderson IR, Lam AC. Polymorphic proteins of Chlamydia spp–autotransporters beyond the Proteobacteria. Trends Microbiol. 2001;9(12):8–573.
   Web of Science ®Google Scholar
• Swanson KA, Taylor LD, Frank SD, et al. Chlamydia trachomatis polymorphic membrane protein D is an oligomeric autotransporter with a higher-order structure. Infect Immun. 2009;77(1):16–508.
   Web of Science ®Google Scholar
• Carrasco JA, Tan C, Rank RG, et al. Altered developmental expression of polymorphic membrane proteins in penicillin-stressed Chlamydia trachomatis. Cell Microbiol. 2011;13(7):25–1014.
   Web of Science ®Google Scholar
• Tan C, Hsia RC, Shou H, et al. Variable expression of surface-exposed polymorphic membrane proteins in in vitro-grown Chlamydia trachomatis. Cell Microbiol. 2010;12(2):87–174.
   Web of Science ®Google Scholar
• Nunes A, Gomes JP, Mead S, et al. Comparative expression profiling of the Chlamydia trachomatis pmp gene family for clinical and reference strains. PLoS One. 2007;2(9):e878.
   PubMed Web of Science ®Google Scholar
• Van Lent S, Creasy HH, Myers GS, et al. Organization, and size of polymorphic membrane protein coding sequences as well as the most conserved pmp protein differ within and across Chlamydia species. J Mol Microbiol Biotechnol. 2016;26(5):44–333.
   Web of Science ®Google Scholar
• Vasilevsky S, Stojanov M, Greub G, et al. Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates. Virulence. 2016;7(1):11–22.
   PubMed Web of Science ®Google Scholar
• Becker E, Hegemann JH. All subtypes of the Pmp adhesin family are implicated in Chlamydial virulence and show species-specific function. Microbiologyopen. 2014;3(4):56–544.
   Web of Science ®Google Scholar
• Paes W, Brown N, Brzozowski AM, et al. Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice. Vaccine. 2016;34(35):31–4123.
   Web of Science ®Google Scholar
• Muller T, Becker E, Stallmann S, et al. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology. Vaccine. 2017;35(21):10–2801.
   PubMed Web of Science ®Google Scholar
• Inic-Kanada A, Stojanovic M, Schlacher S, et al. Delivery of a chlamydial adhesin N-PmpC subunit vaccine to the ocular mucosa using particulate carriers. PLoS One. 2015;10(12):e0144380.
   PubMed Web of Science ®Google Scholar
• Karunakaran KP, Yu H, Jiang X, et al. Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine. Vaccine. 2015;33(18):66–2159.
   Web of Science ®Google Scholar
• Pal S, Favaroni A, Tifrea DF, et al. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge. Vaccine. 2017;35(19):9–2543.
   Web of Science ®Google Scholar
• Yang Z, Tang L, Sun X, et al. Characterization of CPAF critical residues and secretion during Chlamydia trachomatis infection. Infect Immun. 2015;83(6):41–2234.
   Web of Science ®Google Scholar
• Dong F, Zhong Y, Arulanandam B, et al. Production of a proteolytically active protein, Chlamydial protease/proteasome-like activity factor, by five different Chlamydia species. Infect Immun. 2005;73(3):72–1868.
   Web of Science ®Google Scholar
• Wang J, Zhang Y, Lu C, et al. A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J Immunol. 2010;185(3):80–1670.
   Web of Science ®Google Scholar
• Budrys NM, Gong S, Rodgers AK, et al. Chlamydia trachomatis antigens recognized in women with tubal factor infertility, normal fertility, and acute infection. Obstet Gynecol. 2012;119(5):16–1009.
   Web of Science ®Google Scholar
• Rockey DD, Wang J, Lei L, et al. Chlamydia vaccine candidates and tools for Chlamydial antigen discovery. Expert Rev Vaccines. 2009;8(10):77–1365.
   PubMed Web of Science ®Google Scholar
• Li W, Guentzel MN, Seshu J, et al. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin Vaccine Immunol. 2007;14(12):44–1537.
   PubMedGoogle Scholar
• Murthy AK, Li W, Guentzel MN, et al. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge. Vaccine. 2011;29(14):22–2519.
   Web of Science ®Google Scholar
• Li W, Murthy AK, Lanka GK, et al. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice. Vaccine. 2013;31(48):8–5722.
   Web of Science ®Google Scholar
• Wali S, Gupta R, Yu JJ, et al. Chlamydial protease-like activity factor mediated protection against C trachomatis in guinea pigs. Immunol Cell Biol. 2017;95(5):60–454.
   Web of Science ®Google Scholar
• Peterson EM, Markoff BA, Schachter J, et al. The 7.5-kb plasmid present in Chlamydia trachomatis is not essential for the growth of this microorganism. Plasmid. 1990;23(2):8–144.
   Web of Science ®Google Scholar
• Palmer L, Falkow S. A common plasmid of Chlamydia trachomatis. Plasmid. 1986;16(1):52–62.
   PubMed Web of Science ®Google Scholar
• Chen D, Lei L, Lu C, et al. Characterization of Pgp3, a Chlamydia trachomatis plasmid-encoded immunodominant antigen. J Bacteriol. 2010;192(22):24–6017.
   Web of Science ®Google Scholar
• Li Z, Chen D, Zhong Y, et al. The Chlamydial plasmid-encoded protein Pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infect Immun. 2008;76(8):28–3415.
   Web of Science ®Google Scholar
• Liu Y, Huang Y, Yang Z, et al. Plasmid-encoded Pgp3 is a major virulence factor for Chlamydia muridarum to induce hydrosalpinx in mice. Infect Immun. 2014;82(12):35–5327.
   Web of Science ®Google Scholar
• Donati M, Sambri V, Comanducci M, et al. DNA immunization with Pgp3 gene of Chlamydia trachomatis inhibits the spread of Chlamydial infection from the lower to the upper genital tract in C3H/HeN mice. Vaccine. 2003;21(11–12):93–1089.
   Web of Science ®Google Scholar
• Li Z, Wang S, Wu Y, et al. Immunization with Chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice. Sci China C Life Sci. 2008;51(11):80–973.
   PubMedGoogle Scholar
• Luan X, Peng B, Li Z, et al. Vaccination with MIP or Pgp3 induces cross-serovar protection against chlamydial genital tract infection in mice. Immunobiology. 2019;224(2):30–223.
   PubMed Web of Science ®Google Scholar
• O’Meara CP, Armitage CW, Andrew DW, et al. Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology. Vaccine. 2017;35(31):8–3883.
   Web of Science ®Google Scholar
• Yu H, Karunakaran KP, Jiang X, et al. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun. 2012;80(4):8–1510.
   Web of Science ®Google Scholar
• Cheng C, Jain P, Pal S, et al. Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582). Microbes Infect. 2014;16(2):33–123.
   Web of Science ®Google Scholar
• Tifrea DF, Barta ML, Pal S, et al. Computational modeling of TC0583 as a putative component of the Chlamydia muridarum V-type ATP synthase complex and assessment of its protective capabilities as a vaccine antigen. Microbes Infect. 2016;18(4):53–245.
   Web of Science ®Google Scholar
• Kaufhold RM, Boddicker MA, Field JA, et al. Evaluating potential vaccine antigens in both the Chlamydia trachomatis and Chlamydia muridarum Intravaginal mouse challenge models. World J Vaccines. 2019;9(2):49–69.
   Google Scholar
• Koroleva EA, Kobets NV, Shcherbinin DN, et al. Chlamydial Type III secretion system needle protein induces protective immunity against Chlamydia muridarum intravaginal infection. Biomed Res Int. 2017;2017:3865802.
   PubMed Web of Science ®Google Scholar
• LIang S. Intranasal vaccination with a chimeric chlamydial antigen BD584 confers protection against Chlamydia trachomatis genital tract infection. 2020;6(1):7–010. J Clin Vaccine Immunol.
   Google Scholar
• Picard MD, Bodmer JL, Gierahn TM, et al. Resolution of Chlamydia trachomatis infection is associated with a distinct cell response profile. Clin Vaccine Immunol. 2015;22(11):18–1206.
   Google Scholar
• Lu C, Sun Z, Chen H, et al. Proteome array of antibody responses to Chlamydia trachomatis infection in nonhuman primates. Life Sci. 2020;248:117444.
   PubMed Web of Science ®Google Scholar
• Shiragannavar S, Madagi S, Hosakeri J, et al. In silico vaccine design against Chlamydia trachomatis infection. Netw Model Anal Health Inform Bioinform. 2020;9(1):39.
   PubMedGoogle Scholar
• Stojanovic M, Lukic I, Marinkovic E, et al. Cross-reactive effects of vaccines: heterologous immunity between Tetanus and Chlamydia. Vaccines (Basel). 2020;8(4). DOI:10.3390/vaccines8040719.
   PubMed Web of Science ®Google Scholar
• Pal S, Peterson EM. de la Maza LM. New murine model for the study of Chlamydia trachomatis genitourinary tract infections in males. Infect Immun. 2004;72(7):6–4210.
   Web of Science ®Google Scholar
• Pal S, Tifrea DF. de la Maza LM. Characterization of the horizontal and vertical sexual transmission of Chlamydia genital infections in a new mouse model. Infect Immun. 2019;87(7). DOI:10.1128/IAI.00834-18.
   PubMed Web of Science ®Google Scholar
• Kari L, Whitmire WM, Crane DD, et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol. 2009;182(12):70–8063.
   Web of Science ®Google Scholar
• Pal S, Ausar SF, Tifrea DF, et al. Protection of outbred mice against a vaginal challenge by a Chlamydia trachomatis serovar E recombinant major outer membrane protein vaccine is dependent on phosphate substitution in the adjuvant. Hum Vaccin Immunother. 2020;1–11.
   Web of Science ®Google Scholar
• Pal S, Tifrea DF, Follmann F, et al. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge. Vaccine. 2017;35(13):11–1705.
   Web of Science ®Google Scholar
• Johnson RM, Yu H, Kerr MS, et al. PmpG303-311, a protective vaccine epitope that elicits persistent cellular immune responses in Chlamydia muridarum-immune mice. Infect Immun. 2012;80(6):11–2204.
   Web of Science ®Google Scholar
• Nanishi E, Dowling DJ, Levy O. Toward precision adjuvants: optimizing science and safety. Curr Opin Pediatr. 2020;32(1):38–125.
   Web of Science ®Google Scholar
• Yu H, Jiang X, Shen C, et al. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells. Infect Immun. 2010;78(5):82–2272.
   Web of Science ®Google Scholar
• Boddicker MA, Kaufhold RM, Cox KS, et al. A novel LNP-Based Chlamydia subunit vaccine formulation that induces Th1 responses without upregulating IL-17 provides equivalent protection in mice as formulations that induced IL-17 and Th1 cytokines. World j vaccines. 2020;10(4):55–75.
   Google Scholar
• Jiang J, Fisher EM, Hensley SE, et al. Antigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines. Vaccine. 2014;32(23):702–2696.
   Web of Science ®Google Scholar
• Tifrea DF, Pal S, Le Bon C, et al. Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia. Vaccine. 2018;36(45):9–6640.
   Web of Science ®Google Scholar
• Tifrea DF, Pal S, Le Bon C, et al. Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying Amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant. Vaccine. 2020;38(28):22–4412.
   Web of Science ®Google Scholar
• Lewis DJ, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One. 2009;4(9):e6999.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhu C, Zhang T, et al. Nonpathogenic colonization with Chlamydia in the gastrointestinal tract as oral vaccination for inducing transmucosal protection. Infect Immun. 2018;86(2). DOI:10.1128/IAI.00630-17.
   Web of Science ®Google Scholar
• Zhu C, Lin H, Tang L, et al. Oral Chlamydia vaccination induces transmucosal protection in the airway. Vaccine. 2018;36(16):8–2061.
   Web of Science ®Google Scholar
• Christensen D, Mortensen R, Rosenkrands I, et al. Th17 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunol. 2017;10(1):70–260.
   Web of Science ®Google Scholar
• Lorenzen E, Follmann F, Boje S, et al. Intramuscular priming and intranasal boosting induce strong genital immunity through secretory IgA in minipigs infected with Chlamydia trachomatis. Front Immunol. 2015;6:628.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Olsen AW, Lorenzen E, et al. Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge. NPJ Vaccines. 2020;5(1):7.
   Web of Science ®Google Scholar
• Knudsen NP, Olsen A, Buonsanti C, et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep. 2016;6(1):19570.
   PubMedGoogle Scholar
• Rose F, Wern JE, Gavins F, et al. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522. J Control Release. 2018;271:88–97.
   PubMed Web of Science ®Google Scholar
• Tifrea DF, Pal S, Fairman J, et al. Protection against a Chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold. NPJ Vaccines. 2020;5(1):37.
   Web of Science ®Google Scholar
• Jiang P, Du W, Xiong Y, et al. Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital Chlamydial infection. Oncotarget. 2015;6(41):92–43281.
   Google Scholar
• Jiang J, Liu G, Kickhoefer VA, et al. A protective vaccine against Chlamydia genital infection using vault nanoparticles without an added adjuvant. Vaccines (Basel). 2017;5(1). DOI:10.3390/vaccines5010003.
   PubMed Web of Science ®Google Scholar
• Badamchi-Zadeh A, McKay PF, Korber BT, et al. A multi-component prime-boost vaccination regimen with a consensus MOMP antigen enhances Chlamydia trachomatis clearance. Front Immunol. 2016;7:162.
   PubMed Web of Science ®Google Scholar
• Sahu R, Dixit S, Verma R, et al. A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4(+) effector (CD44(high) CD62L(low)) and memory (CD44(high) CD62L(high)) T-cells in immunized mice. Nanomedicine. 2020;29:102257.
   PubMed Web of Science ®Google Scholar
• Jiang P, Cai Y, Chen J, et al. Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model. Vaccine. 2017;35(23):103–3096.
   Web of Science ®Google Scholar
• Wang L, Cai Y, Xiong Y, et al. DNA plasmid vaccine carrying Chlamydia trachomatis (Ct) major outer membrane and human papillomavirus 16L2 proteins for anti-Ct infection. Oncotarget. 2017;8(20):51–33241.
   PubMedGoogle Scholar
• Pais R, Omosun Y, Igietseme JU, et al. Route of vaccine administration influences the impact of fms-like tyrosine kinase 3 Ligand (Flt3L) on Chlamydial-specific protective immune responses. Front Immunol. 2019;10:1577.
   PubMed Web of Science ®Google Scholar
• Kuczkowska K, Myrbraten I, Overland L, et al. Lactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization. PLoS One. 2017;12(5):e0176401.
   PubMed Web of Science ®Google Scholar
• Sahu R, Verma R, Dixit S, et al. Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles. Expert Rev Vaccines. 2018;17(3):27–217.
   Web of Science ®Google Scholar
• Rodrigues L, Raftopoulos KN, Tandrup Schmidt S, et al. Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein. J Control Release. 2018;285:12–22.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):9–401.
   Web of Science ®Google Scholar
• Cheng C, Pal S, Tifrea D, et al. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect. 2014;16(3):52–244.
   Web of Science ®Google Scholar
• Su F, Patel GB, Hu S, et al. Induction of mucosal immunity through systemic immunization: phantom or reality? Hum Vaccin Immunother. 2016;12(4):9–1070.
   Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):11–401.
   PubMed Web of Science ®Google Scholar
• Plotnikoff KM, Ogilvie GS, Smith L, et al. Factors associated with interest in bacterial sexually transmitted infection vaccines at two large sexually transmitted infection clinics in British Columbia, Canada. Sex Transm Infect. 2020;96(7):494–500.
   PubMed Web of Science ®Google Scholar
• Ditkowsky J, Rahman A, Hammerschlag MR, et al. Cost-benefit analysis of a Chlamydia trachomatis vaccine program in adolescent girls in the United States. J Pediatric Infect Dis Soc. 2018;7(4):296–302.
   PubMed Web of Science ®Google Scholar
• Owusu-Edusei K Jr., Chesson HW, Gift TL, et al. Cost-effectiveness of Chlamydia vaccination programs for young women. Emerg Infect Dis. 2015;21(6):8–960.
   PubMed Web of Science ®Google Scholar
• de la Maza MA. de la Maza LM. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine. 1995;13(1):27–119.
   Web of Science ®Google Scholar